Public Board of Directors papers 27.01.22

EXECUTIVE SUMMARY

Introduction

The Integrated Performance, Quality & Finance report presents a summary dashboard that provides an overview of performance.

Safe • No serious incidents were reported in December. There was 1 incident reported with the classification of death, 2 as major, and 4 as moderate incidents in December, details of which can be found on slide 8. All the incidents are still progressing through to full root cause analysis. No never events were reported in month.

• Slide 9 provides details of shared learning from incidents following Executive Reviews. • There are 4 Trust level risks scored at 15+. Details of these can be found on slide 12. Responsive

• The 62 day cancer waiting time standard has not been met in December. Our position subject to validation is 73.4%. The 62 day standard for upgrades has been achieved. Within the 62 day performance we also failed to achieve the internal 24 day standard with a performance of 81.6%. All 62 and 24 day breaches are reviewed to ensure any delays are understood and plans can be implemented to mitigate any future delays . The number of patients waiting over 104 days as at the end of the month remained high. The large majority of these patients are referred to the Trust over day 100. All 31 day targets and 18 week RTT standards have been achieved in December. Performance against the CWT thresholds is constantly monitored. • Referrals in December are back at levels consistent with 2019/20. • Activity levels in most aspects are above GM recovery plans and in some areas back to 2019/20 levels. The classification issue with new attendances has now been resolved and 21/22 totals are now showing as above 19/20 levels, as are outpatient follow ups. Surgical operations and radiotherapy fractions remain behind 19/20 levels. Effective • There have been no cases of MRSA bacteraemia. There have been 6 cases of C-Difficile that were attributable to the trust in month with no lapse in care identified. • There were 5 cases of hospital acquired nosocomial Covid-19 infections in month. Well – Led • The trust position as at month 9 is a year to date surplus of £1.662m (in month surplus of £11k against an agreed nil balance control total for the year which reflects the new GM financial arrangements in place for M1-12). • The month 9 I&E surplus is £16.743m, prior to adjusting for donated depreciation, charitably funded capital donations, donated grant income and impairments. • The cash balance is £156,590k • The Trust is showing a Capital underspend at Month 9 of £3,792k, which equates to 5.1% underperformance against the NHSEI plan and £1,833k (-2.5%) underperformance against the reduced £2.5m NHSI plan. The main expenditure incurred has been on the Paterson development, the Macclesfield satellite, the tiered car park and progress on the Carbon Energy Fund infrastructure improvement programme (both Trust and government grant funded).

146